An Open-Label Pilot Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of ABT-450 With Ritonavir (ABT-450/r) Dosed in Combination With ABT-072 and Ribavirin (RBV) in Treatment-Naive Subjects With Genotype 1 Chronic Hepati
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials
| City: |
|
Beverly Hills |
| State: |
|
California |
| Zip Code: |
|
90211 |
| Conditions: |
|
Hepatitis C - HCV - Chronic Hepatitis C - Hepatitis C Genotype 1 |
| Purpose: |
|
A 12-week study of combination direct-acting antiviral agents (DAAs) and Ribavirin (RBV) in
subjects with chronic Hepatitis C Virus (HCV).
|
| Study Summary: |
|
|
| Criteria: |
|
Inclusion Criteria
- Chronic hepatitis C, genotype 1 infection (IL28B rs12979860 genotype C/C).
- Liver biopsy within 3 years with histology consistent with HCV-induced liver damage,
with no evidence of cirrhosis or liver pathology due to any cause other than chronic
Hepatitis C Virus.
- Treatment naïve male or female between the ages of 18 and 65.
- Females must be post-menopausal for at least 2 years or surgically sterile.
- Be in a condition of general good health, as perceived by the investigator, other
than Hepatitis C Virus infection.
Exclusion Criteria
- Significant sensitivity to any drug.
- Use of herbal supplements within 2 weeks prior to study drug dosing.
- Positive screen for drugs and alcohol.
- Positive Hepatitis surface Antigen and anti-Human Immunodeficiency Virus Antibody.
- Use of CYP3A, CYP2C8, and OATP1B1 enzyme inducers or inhibitors within 1 month of
dosing.
- Prior treatment with any investigational or commercially available anti-Hepatitis C
Virus agents.
- Abnormal laboratory tests.
|
| NCT ID: |
|
NCT01221298 |
| Primary Contact: |
|
Study Director
Daniel Cohen, MD
Abbott
|
| Backup Contact: |
|
N/A |
| Location Contact: |
|
Beverly Hills, California 90211
United States
There is no listed contact information for this specific location.
Site Status: N/A |
| Data Source: |
|
ClinicalTrials.gov |
| Date Processed: |
|
May 22, 2013 |
| Modifications to this listing: |
|
Only selected fields are shown, please use the link
below to view all information about this clinical trial. |
|
Click to view Full Listing
|